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Abstract
Background: Optimal phosphorous control is an important aspect of the care of patients with end-stage renal
disease, and phosphate binders are usually needed.
Case presentation: A 74-year-old woman with end-stage renal disease on maintenance hemodialysis presented to
the emergency room with abdominal discomfort, rectal pain, and blood-tinged stools. Initial concern was for a
rectal carcinoma, based on the symptoms and imaging in initial computerized tomography of the abdomen
showing rectal wall thickening, and her clinical presentation. She had been treated with the phosphate binder
sevelamer for two months. In this case report, we explore the unique features of sevelamer-associated recto-
sigmoid ulcers which led to her symptoms.
Conclusion: Sevelamer is widely used in chronic kidney disease and end-stage renal disease patients with
hyperphosphatemia. It is a crosslinked polymeric amine that binds phosphates and bile acids; it is not systemically
absorbed. To the authors’ knowledge, this is the first reported case of recto-sigmoid ulcers associated with use of
this phosphate binder. Nephrologists, pathologists, and gastroenterology sub-specialists should be aware of this
recently-reported entity in patients on sevelamer with suggestive symptoms, as this medication is widely used in
renal patients.
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Background
Hyperphosphatemia is one of the most frequent meta-
bolic derangements seen in end-stage renal disease
(ESRD). Large observational studies have identified
hyperphosphatemia as an independent risk factor for
cardiovascular disease and mortality for patients on dia-
lysis, and subsequent studies have found that subtle in-
creases in serum phosphate levels within the normal
range are also associated with increased risk for death
in predialysis and even non–kidney disease popula-
tions [1–3]. Current practice guidelines recommend
more aggressive management of hyperphosphatemia to
lower serum phosphate targets than in the past [1, 4, 5].
Simultaneously, there has been an increase in utilization
of non-calcium phosphate binders and several new resin-
based products that have been approved by the Food and
Drug Administration (FDA) for this indication, including
sevelamer hydrochloride, a non-absorbed synthetic poly-
mer [6–9]. Renvela (sevelamer carbonate) was FDA-
approved in March 2008 and was preceded by sevelamer
hydrochloride [9]. The market represents an estimated $1
billion for this drug alone in worldwide sales [10]. Various
gastrointestinal side effects have been reported including
vomiting (22 %), nausea (20 %), diarrhea (19 %), dyspepsia
(16 %), abdominal pain (9 %), constipation (8 %) and asso-
ciated stercoral ulceration, flatulence (8 %), intestinal ob-
struction, and fecal impaction [11–14]. However, there is
little information regarding gastrointestinal ulceration as a
side effect; only a report of sevelamer crystals isolated
from the gastrointestinal tracts of patients with symptoms
of gastrointestinal distress have been identified in the
literature [15].* Correspondence: Hogan.Marie@mayo.edu
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Case presentation
A 74-year-old woman with ESRD secondary to diabetes
and maintained on hemodialysis three times per week
presented to the Emergency Department with constipa-
tion, lower abdominal discomfort, prominent rectal pain,
and blood-tinged stools. She had no watery diarrhea.
Physical exam was significant for diffuse abdominal ten-
derness. Initial work up was significant for stable
complete blood count and basic metabolic panel, with a
stool specimen positive for C. difficile toxin by PCR in
the context of recently treated C. difficile infection. Not-
ably, symptoms were different from her prior episode of
C. difficile associated diarrhea 11 months earlier. This
was felt to be representative of a prior infection. Com-
puted tomography (CT) of the abdomen and pelvis re-
vealed non-specific circumferential rectal thickening
with fat stranding suggestive of an inflammatory/infec-
tious or malignant process (Fig. 1).
Sigmoidoscopy with biopsies was performed to establish
a diagnosis, which revealed circumferential ulcerations,
exudates, and purplish hue to the mucosa in the mid- and
distal rectum consistent with ischemia. No classic endo-
scopic findings consistent with C. difficile infection, such
as pseudomembranes, were identified.
Endoscopic biopsies of the rectal ulcerations revealed
pill fragments consistent with sevelamer crystals in the
exudate. Sevelamer crystals in the fibropurulent/ nec-
rotic debris identified on histology displayed a character-
istic “fish scale” pattern [2] as shown in Fig. 2. No
crystals were present within the preserved tissue frag-
ments in the sample. Overall the findings were that of
an ulcer without specific features to point to any other
particular etiology (e.g. inflammatory bowel disease, is-
chemia etc.). The patient had commenced sevelamer
(Renvela 1,600 mg orally 3 times a day) approximately
2 months prior to her presentation. Sevelamer-induced
mucosal injury was confirmed, the medication was dis-
continued, and treatment with calcium acetate was
substituted. Her constipation resolved with conservative
medical management. Her incidentally positive C. difficile
Fig 1 a and b Rectal mucosa with ulcerations, exudates, and purplish hue. c CT scan showing circumferential rectal wall thickening (arrow) with
adjacent fat stranding and apparent adhesion to the mesorectal fascia
Fig 2 Characteristic histologic appearance of sevelamer pill fragments, featuring crystalloid structures with broad, slightly-curved, irregular “fish
scales” with a two-toned (pink and tan-yellow) color seen on mucosal biopsy. (Hematoxylin and eosin stain, 400x magnification)
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PCR was not felt to represent true infection, but was
conservatively treated with a 10-day course of oral
vancomycin.
Discussion
Sevelamer-associated gastrointestinal mucosal injury is a
relatively novel entity among sevelamer users that has
not yet been fully characterized. In addition, its non-
specific presentation on both CT imaging and endoscopy
may lead to delayed recognition and under-diagnosis.
Therefore, physicians should have a high index of suspi-
cion to pursue further evaluation.
Unfortunately, an understanding of the incidence of
sevelamer-associated gastrointestinal ulceration is limited
by the sparse literature that is currently available. Re-
ported sites of gastrointestinal mucosal involvement in-
clude the esophagus (n = 2), small bowel (n = 2), and colon
(n = 12; including this case). It is currently unclear
whether sevelamer was the causative agent of mucosal in-
jury, or whether the association was coincidental in ESRD.
However, we do not believe that sevelamer was inciden-
tally adherent to the mucosa as a result of an underlying
colonic disease process, including IBD, CMV colitis or di-
verticulitis, since no such intestinal pathology was docu-
mented on the biopsies. We, therefore, favor that
sevelamer was the primary cause for the rectal ulcers.
While we would have liked to confirm resolution of mu-
cosal involvement following discontinuation of sevelamer
to be 100 % confident of causality, this was not feasible
due to burden of care relating to complications of kidney
disease (access surgery, dialysis visits) lack of eligibility of
kidney transplant and other comorbidities (endocarditis,
eye surgery, diabetes care visits, hospitalization for cere-
bral infarction) that limit her life span with additional en-
doscopy being unlikely to improve quality of life or
survival [16].
Conclusions
We report the first clinical description of sevelamer in-
duced rectal ulcers in a hemodialysis patient presenting
with abdominal and rectal pain, constipation, and a mass
on CT. Initial concern in this case was for a rectal carcin-
oma, which was ruled out with rectal mucosal biopsies
showing characteristic sevelamer crystals. Furthermore,
the mechanism by which sevelamer may have induced
mucosal injury is unknown. In patients taking sevelamer,
nephrologists, gastroenterologists and pathologists should
be aware of the drug’s characteristic morphology to permit
accurate diagnosis on biopsy and to reliably distinguish it
from other gastrointestinal conditions.
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